Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.

rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis

Open access
Shen, Weiran, Liu, Shengjiang, Ou, Li · 2022 · Frontiers in Immunology

Abstract

Recombinant Adeno-associated virus (rAAV) is one of the main delivery vectors for gene therapy. To assess immunogenicity, toxicity, and features of AAV gene therapy in clinical settings, a meta-analysis of 255 clinical trials was performed. A total of 7,289 patients are planned to be dosed. AAV2 was the most dominantly used serotype (29.8%, n=72), and 8.3% (n=20) of trials used engineered capsids. 38.7% (n=91) of trials employed neutralizing antibody assays for patient enrollment, while 15.3% (n=36) used ELISA-based total antibody assays. However, there was high variability in the eligibility criteria with cut-off tiers ranging from 1:1 to 1:1,600. To address potential immunogenicity, 46.3% (n=118) of trials applied immunosuppressants (prophylactic or reactive), while 32.7% (n=18) of CNS and 37.5% (n=24) of ocular-directed trials employed immunosuppressants, possibly due to the immune-privileged status of CNS and retina. There were a total of 11 patient deaths across 8 trials, and 18 out of 30 clinical holds were due to toxicity findings in clinical studies. 30.6% (n=78) of trials had treatment-emergent serious adverse events (TESAEs), with hepatotoxicity and thrombotic microangiopathy (systemic delivery) and neurotoxicity (CNS delivery) being the most prominent. Additionally, the durability of gene therapy may be impacted by two distinct decline mechanisms: 1) rapid decline presumably due to immune responses; or 2) gradual decline due to vector dilution. The durability varied significantly depending on disease indication, dose, serotypes, and patient individuals. Most CNS (90.0%) and muscle trials (73.3%) achieved durable transgene expression, while only 43.6% of ocular trials had sustained clinical outcomes. The rAAV production system can affect rAAV quality and thus immunogenicity and toxicity. Out of 186 trials that have disclosed production system information, 63.0% (n=126) of trials used the transient transfection of the HEK293/HEK293T system, while 18.0% (n=36) applied the baculovirus/Sf9 (rBac/Sf9) system. There were no significant differences in TESAEs and durability between AAV generated by rBac/Sf9 and HEK293/HEK293T systems. In summary, rAAV immunogenicity and toxicity poses significant challenges for clinical development of rAAV gene therapies, and it warrants collaborative efforts to standardize monitoring/measurement methods, design novel strategies to overcome immune responses, and openly share relevant information.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2022.1001263

Cites

89 of 89 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Basic information of 255 AAV clinical trials by status and phases (A), disease indications (B), ROAs and serotypes (C), and sponsors (D). ROA and serotypes associated with <10 trials are not included in the figure. IT and ICM were combined due to the high similarity. Unknown status suggests that study has passed its completion date and status has not been verified in more than two years.
Figure 1 Basic information of 255 AAV clinical trials by status and phases (A), disease indications (B), ROAs and serotypes (C), and sponsors (D). ROA and serotypes associated with <10 trials are not included in the figure. IT and ICM were combined due to the high similarity. Unknown status suggests that study has passed its completion date and status has not been verified in more than two years.CC BY · PubMed Central
Figure 2 Immunosuppressants usage of 255 AAV clinical trials by disease indications (A), timeframe (B), serotypes (C), and ROAs (D). ROA and serotypes associated with <10 trials are not included in the figure. IT and ICM were combined due to the high similarity.
Figure 2 Immunosuppressants usage of 255 AAV clinical trials by disease indications (A), timeframe (B), serotypes (C), and ROAs (D). ROA and serotypes associated with <10 trials are not included in the figure. IT and ICM were combined due to the high similarity.CC BY · PubMed Central
Figure 3 Antibody assays of 255 AAV clinical trials by disease indications (A), timeframe (B), serotypes (C), and ROAs (D). ROA and serotypes associated with <10 trials are not included in the figure. IT and ICM were combined due to the high similarity. Trials that indicated usage of antibody assays but did not specify types of assays are not included.
Figure 3 Antibody assays of 255 AAV clinical trials by disease indications (A), timeframe (B), serotypes (C), and ROAs (D). ROA and serotypes associated with <10 trials are not included in the figure. IT and ICM were combined due to the high similarity. Trials that indicated usage of antibody assays but did not specify types of assays are not included.CC BY · PubMed Central
Figure 4 Reported TESAEs of 255 AAV clinical trials by disease indications (A), ROAs (B), serotypes (C), and manufacturing systems (D). ROA and serotypes associated with <10 trials are not included in the figure. IT and ICM were combined due to the high similarity. Trials that initiated recently are not included for analysis.
Figure 4 Reported TESAEs of 255 AAV clinical trials by disease indications (A), ROAs (B), serotypes (C), and manufacturing systems (D). ROA and serotypes associated with <10 trials are not included in the figure. IT and ICM were combined due to the high similarity. Trials that initiated recently are not included for analysis.CC BY · PubMed Central
Figure 5 Reported durability of 255 AAV clinical trials by disease indications (A), manufacturing systems (B), serotypes (C), and ROAs (D). ROA and serotypes associated with <10 trials are not included in the figure. IT and ICM were combined due to the high similarity. Trials that initiated recently or did not report efficacy and transgene expression data are not included for analysis.
Figure 5 Reported durability of 255 AAV clinical trials by disease indications (A), manufacturing systems (B), serotypes (C), and ROAs (D). ROA and serotypes associated with <10 trials are not included in the figure. IT and ICM were combined due to the high similarity. Trials that initiated recently or did not report efficacy and transgene expression data are not included for analysis.CC BY · PubMed Central
Figure 6 Manufacturing systems of 255 AAV clinical trials. (A) System usage in different time periods. (B) Patient deaths in trials using different manufacturing systems. Trials that did not report manufacturing systems are not included for analysis.
Figure 6 Manufacturing systems of 255 AAV clinical trials. (A) System usage in different time periods. (B) Patient deaths in trials using different manufacturing systems. Trials that did not report manufacturing systems are not included for analysis.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 88 references

Research works printed but not linked: 1

  1. Bonnemann, 2020, AAV related immunological safety and toxicity: Preliminary clinical observations in the GAN and MTM1 trials

Cited by

See all 184

Metadata

Authors
Shen, W., Liu, S., & Ou, L.
Affiliations
University of Minnesota (US)
Corresponding author
Ou, Li
Venue
Frontiers in Immunology
Published
2022-10-27
Volume
13
Pages
1001263-1001263
ISSN
1664-3224 (ISSN-L)
OpenAlex
W4307633692
Cited by
173
References
88
Citations by year
2026: 40 · 2025: 60 · 2024: 47 · 2023: 26
FWCI
5.13
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
recombinant adeno-associated virus, AAV gene therapy, immunogenicity, toxicity, neutralizing antibodies, immunosuppression, hepatotoxicity, thrombotic microangiopathy, neurotoxicity, ocular gene therapy, CNS gene therapy, HEK293 cells
MeSH terms
Dependovirus, Genetic Vectors, Humans, Immunosuppressive Agents, Genetic Therapy, HEK293 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis. https://app.cochat.ai/papers/10.3389/fimmu.2022.1001263
The paper
Shen, W., Liu, S., & Ou, L. (2022). rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2022.1001263

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.